Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
复制标题
Transgelin：在三阴性和非三阴性乳腺癌中差异表达的潜在有用的诊断标记。
DOI：
10.1016/j.humpath.2015.02.015
复制
发表时间：
2015-06
期刊：
影响因子：
3.3
通讯作者：
Tawfik, Ossama
中科院分区：
文献类型：
--
作者：
Rao, Deepthi;Kimler, Bruce F.;Nothnick, Warren B.;Davis, Marilyn K.;Fan, Fang;Tawfik, Ossama
Triple negative (TN) (estrogen receptor [ER], progesterone receptor [PR] and Her2 negative) are highly aggressive, rapidly growing, hormone unresponsive tumors diagnosed at later stage that affect younger women with shorter overall survival. The majority of TN tumors are of the basal type. For the remainder identification of target markers for effective treatment strategies remains a challenge. Transgelin (TGLN) is a 22 kDa actin-binding protein of the calponin family. It is one of the earliest markers of smooth muscle differentiation. TGLN has been shown to have important biologic activities including regulating muscle fiber contractility, cell migration and tumor suppression. We examined TGLN expression in the different molecular subtypes of breast cancer. TGLN expression was examined as a function of tumor size, grade, histologic type, lymph node (LN) status, patients’ age and overall survival, ER, PR, Her-2, Ki-67 in 101 tumors that included 35 luminal A, 28 luminal B, 4 Her2, and 34 TN types. TGLN positivity (defined as 2+ or 3+) was associated with more aggressive tumors (10% of grade I/II tumors were TGLN+ vs. 53% of grade III tumors, P<0.001), high Ki-67 count and low ER and PR expression (p<0.001), but not with tumor size, age or LN metastasis. TN (n=34) tumors were 7.7 times more likely to be TGLN-positive than non-TN (n=67) tumors (77% vs. 10%, respectively, P<0.001). TGLN may be an excellent diagnostic marker of TN tumors and could be useful in stratification of patients. TGLN may also prove a potential target for future treatment strategies.
登录
查看更多内容
DOI：
10.1016/j.biocel.2008.02.011
发表时间：
2009-03-01
影响因子：
4
作者：
Assinder, Stephen J.;Stanton, Jo-Ann L.;Prasad, Priya D.
通讯作者：
Prasad, Priya D.
影响因子：
7.9
作者：
Cai, Jiangxia;Chen, Siying;Dong, Yalin
通讯作者：
Dong, Yalin
影响因子：
4.8
作者：
Lin, Ying;Buckhaults, Phillip J.;Dynan, William S.
通讯作者：
Dynan, William S.
影响因子：
4.8
作者：
Shields, JM;Rogers-Graham, K;Der, CJ
通讯作者：
Der, CJ
影响因子：
4.4
作者：
Hu, Zhiyuan;Fan, Cheng;Perou, Charles M.
通讯作者：
Perou, Charles M.